A Phase 2 interventional study of Brigimadlin in Pancreatic Neoplasms, Solid Tumors and Biliary Tract Cancer, sponsored by Boehringer Ingelheim. Completed at 60 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.
Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 348th largest by enrollment of the 1,573 interventional ones that give a count, is one of 88 that started in 2022, is one of 488 in phase 2, and was the 1,546th registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Anova Innovation Limited · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
IMGT Co., Ltd. · Sites in United States, Korea, Republic of
Ages 18–85
AdventHealth · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,850 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 777 · Phase 2 721 · Phase 3 91 · Phase 4 12
First in 1991; this study’s year is marked. 88 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 37 across the 1,573 interventional studies, 137 across the 230 observational. Of the 1,223 that completed or were terminated, 479 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
576 of 1,850 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 61 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 6 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
161 of the studies in Pancreatic Neoplasms with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05720338Phase 3Case Comprehensive Cancer CenterIs Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? | 2026-12-31 |
| NCT03257033Phase 3RenovoRxIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | 2027-06 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT04275557H. Lee Moffitt Cancer Center and Research InstituteUsing Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas | 2026-11 |
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
Add all 161 to your calendar (.ics) → With an account.
Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists.
The purpose of this study is to find out whether a medicine called BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. All participants take BI 907828 as a tablet once every 3 weeks. Participants may continue to take BI 907828 as long as they benefit from treatment and can tolerate it. They visit the study site regularly. At the study site, doctors regularly check the size of the tumour and whether it has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of a solid tumour which meets the criteria for an open trial cohort:
Exclusion Criteria:
Further exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with locally advanced / metastatic MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma received brigimadlin 45 milligram (mg) orally on Day 1 of each 21-day cycle. Patients continued to receive treatment with brigimadlin until disease progression (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST) or until another reason requiring termination of treatment.
Drug: Brigimadlin
Patients with locally advanced / metastatic MDM2 amplified, TP53 wild-type pancreatic ductal adenocarcinoma received brigimadlin 45 mg orally on Day 1 of each 21-day cycle. Patients continued to receive treatment with brigimadlin until disease progression (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST) or until another reason requiring termination of treatment.
Drug: Brigimadlin
Patients with locally advanced / metastatic MDM2 amplified, TP53 wild-type lung adenocarcinoma received brigimadlin 45 mg orally on Day 1 of each 21-day cycle. Patients continued to receive treatment with brigimadlin until disease progression (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST) or until another reason requiring termination of treatment.
Drug: Brigimadlin
Patients with locally advanced / metastatic MDM2 amplified, TP53 wild-type urothelial bladder cancer received brigimadlin 45 mg orally on Day 1 of each 21-day cycle. Patients continued to receive treatment with brigimadlin until disease progression (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST) or until another reason requiring termination of treatment.
Drug: Brigimadlin
Patients received brigimadlin 45 mg orally on Day 1 of each 21-day cycle.
Also known as: BI 907828
Objective Response (OR)
OR based on central independent review is reported. OR is defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.
Time frame: From the date of treatment start until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 25.0 months.
Duration of Objective Response (DOR)
DOR based on central independent review is reported. DOR was defined as the time from first documented confirmed objective response (OR) until the earliest date of disease progression or death among patients with confirmed objective response.
Time frame: From first documented confirmed objective response (OR) until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 23.9 months.
Progression-free Survival (PFS)
PFS based on central independent review. PFS was defined as the time from treatment start until the earliest date of tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs first.
Time frame: From treatment start until the earliest date of tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs first. Up to 25.0 months.
Overall Survival (OS)
OS was defined as the time from treatment start until death from any cause.
Time frame: From treatment start until death from any cause. Up to 28.1 months.
Disease Control (DC)
DC based on central independent review is reported. DC was defined as a best overall response of CR, PR, or stable disease (SD) where best overall response is defined according to RECIST version 1.1.
Time frame: From the date of treatment start until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 25.0 months.
Occurrence of Treatment-emergent Adverse Events (AEs) During the On-treatment Period
Occurrence of treatment-emergent AEs during the on-treatment period is reported as count of participants with treatment-emergent AEs during the on-treatment period.
Time frame: From first day of administration of brigimadlin until last administration of brigimadlin plus 30 days of residual effect period (REP), up to 28.4 months.
Occurrence of Treatment-emergent AEs Leading to Trial Drug Discontinuation During the On-treatment Period
Occurrence of treatment-emergent AEs leading to trial drug discontinuation during the on-treatment period is reported as count of participants with treatment-emergent AEs leading to trial drug discontinuation during the on-treatment period.
Time frame: From first day of administration of brigimadlin until last administration of brigimadlin plus 30 days of residual effect period (REP), up to 28.4 months.
This was a Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic, Murine Double Minute 2 (MDM2) amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours.
| Milestone | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) |
|---|---|---|---|---|
| Started | 67 | 10 | 11 | 11 |
| Treated with trial medication | 66 | 10 | 11 | 11 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 67 | 10 | 11 | 11 |
| Withdrew: Other reason than listed | 8 | 3 | 1 | 1 |
| Withdrew: Withdrawal by subject | 7 | 0 | 2 | 2 |
| Withdrew: Adverse event | 5 | 0 | 1 | 1 |
| Withdrew: Clinical disease progression | 6 | 3 | 1 | 1 |
| Withdrew: Objective disease progression | 40 | 4 | 6 | 6 |
| Withdrew: Not treated | 1 | 0 | 0 | 0 |
OR based on central independent review is reported. OR is defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.
| percentage of participants | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) |
|---|---|---|---|---|
| Objective Response (OR) | 18.2 (9.76 to 29.61) | 0.0 (0.00 to 30.85) | 45.5 (16.75 to 76.62) | 18.2 (2.28 to 51.78) |
DOR based on central independent review is reported. DOR was defined as the time from first documented confirmed objective response (OR) until the earliest date of disease progression or death among patients with confirmed objective response.
| months | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) |
|---|---|---|---|---|
| Duration of Objective Response (DOR) | 8.50 (5.40 to 15.60) | — | 9.10 (5.40 to NA) | 3.75 (3.00 to NA) |
PFS based on central independent review. PFS was defined as the time from treatment start until the earliest date of tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs first.
| months | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) |
|---|---|---|---|---|
| Progression-free Survival (PFS) | 4.20 (3.00 to 5.00) | 1.40 (1.20 to NA) | 8.00 (3.00 to 14.00) | 3.10 (1.40 to 5.10) |
OS was defined as the time from treatment start until death from any cause.
| months | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) |
|---|---|---|---|---|
| Overall Survival (OS) | 10.10 (6.90 to 12.30) | 4.30 (3.10 to 7.80) | NA (6.60 to NA) | 5.10 (2.00 to 11.10) |
DC based on central independent review is reported. DC was defined as a best overall response of CR, PR, or stable disease (SD) where best overall response is defined according to RECIST version 1.1.
| percentage of participants | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) |
|---|---|---|---|---|
| Disease Control (DC) | 75.8 (63.64 to 85.46) | 40.0 (12.16 to 73.76) | 90.9 (58.72 to 99.77) | 54.5 (23.38 to 83.25) |
Occurrence of treatment-emergent AEs during the on-treatment period is reported as count of participants with treatment-emergent AEs during the on-treatment period.
| Participants | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) |
|---|---|---|---|---|
| Occurrence of Treatment-emergent Adverse Events (AEs) During the On-treatment Period | 65 | 10 | 11 | 11 |
Occurrence of treatment-emergent AEs leading to trial drug discontinuation during the on-treatment period is reported as count of participants with treatment-emergent AEs leading to trial drug discontinuation during the on-treatment period.
| Participants | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) |
|---|---|---|---|---|
| Occurrence of Treatment-emergent AEs Leading to Trial Drug Discontinuation During the On-treatment Period | 4 | 0 | 0 | 1 |
Collected over "All-Cause Mortality", "Serious Adverse Events" and "Other Adverse Events": From first day of administration of brigimadlin until last administration of brigimadlin plus 30 days of residual effect period (REP), up to 28.4 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | 52/66 (78.8%) | 37/66 (56.1%) | 65/66 (98.5%) |
| Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | 8/10 (80%) | 6/10 (60%) | 10/10 (100%) |
| Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | 4/11 (36.4%) | 5/11 (45.5%) | 11/11 (100%) |
| Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) | 7/11 (63.6%) | 4/11 (36.4%) | 11/11 (100%) |
| Event | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) |
|---|---|---|---|---|
| Biliary tract infectionInfections and infestations | 2/66 | 2/10 | 0/11 | 0/11 |
| SepsisInfections and infestations | 1/66 | 0/10 | 0/11 | 2/11 |
| Platelet count decreasedInvestigations | 7/66 | 1/10 | 0/11 | 0/11 |
| AnaemiaBlood and lymphatic system disorders | 4/66 | 1/10 | 0/11 | 0/11 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 0/66 | 1/10 | 0/11 | 0/11 |
| PancreatitisGastrointestinal disorders | 1/66 | 1/10 | 0/11 | 0/11 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/66 | 1/10 | 0/11 | 0/11 |
| PyrexiaGeneral disorders | 0/66 | 1/10 | 0/11 | 0/11 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/66 | 1/10 | 0/11 | 1/11 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/66 | 1/10 | 1/11 | 0/11 |
| Event | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 28/66 | 4/10 | 3/11 | 7/11 |
| NauseaGastrointestinal disorders | 40/66 | 6/10 | 6/11 | 3/11 |
| Platelet count decreasedInvestigations | 39/66 | 6/10 | 5/11 | 6/11 |
| Neutrophil count decreasedInvestigations | 29/66 | 1/10 | 4/11 | 2/11 |
| Decreased appetiteMetabolism and nutrition disorders | 25/66 | 4/10 | 3/11 | 3/11 |
| NeutropeniaBlood and lymphatic system disorders | 10/66 | 1/10 | 4/11 | 2/11 |
| Oedema peripheralGeneral disorders | 6/66 | 2/10 | 4/11 | 2/11 |
| DiarrhoeaGastrointestinal disorders | 19/66 | 3/10 | 2/11 | 1/11 |
| MalaiseGeneral disorders | 9/66 | 3/10 | 3/11 | 1/11 |
| ThrombocytopeniaBlood and lymphatic system disorders | 13/66 | 0/10 | 3/11 | 2/11 |
Treated Set (TS): This patient set includes all patients who were dispensed trial medication and were documented to have taken at least one dose of trial medication.
| Age, Continuous(Years) | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) | Total |
|---|---|---|---|---|---|
| Mean | 62.6 ± 10.1 | 62.9 ± 11.3 | 66.6 ± 10.9 | 70.3 ± 8.9 | 63.9 ± 10.3 |
| Sex: Female, Male(Participants) | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) | Total |
|---|---|---|---|---|---|
| Female | 32 | 3 | 5 | 2 | 42 |
| Male | 34 | 7 | 6 | 9 | 56 |
| Race (NIH/OMB)(Participants) | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 41 | 8 | 3 | 8 | 60 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 1 | 1 | 4 |
| White | 21 | 2 | 7 | 2 | 32 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 0 | 0 | 2 |
| Country of enrollment(Participants) | Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma) | Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma) | Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma) | Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer) | Total |
|---|---|---|---|---|---|
| Australia | 2 | 0 | 0 | 0 | 2 |
| Belgium | 2 | 0 | 1 | 0 | 3 |
| Germany | 2 | 0 | 0 | 1 | 3 |
| Spain | 7 | 1 | 1 | 1 | 10 |
| France | 2 | 0 | 0 | 0 | 2 |
| United Kingdom | 1 | 0 | 0 | 0 | 1 |
| Japan | 15 | 5 | 2 | 1 | 23 |
| Korea, Republic of | 20 | 0 | 1 | 7 | 28 |
| Singapore | 1 | 0 | 0 | 0 | 1 |
| Thailand | 1 | 0 | 0 | 0 | 1 |
| Taiwan | 3 | 2 | 0 | 0 | 5 |
| United States of America | 10 | 2 | 4 | 1 | 17 |
| Switzerland | 0 | 0 | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com
Ran from Dec 2022 to primary completion in Sep 2025, 33 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 33 months is close to that.
Counting every sponsor, half of 396 studies reached it within 57 months; a quarter within 35 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brigimadlin